Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

[1]  Richard Van Noorden nature news 実験室は、安全な職場ではない , 2013 .

[2]  H. Tanii,et al.  A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors , 2012, Investigational New Drugs.

[3]  K. J. Henley,et al.  Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. , 2011, Blood.

[4]  S. Lonial,et al.  Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes , 2011, Leukemia.

[5]  S. Ramalingam,et al.  Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Lane,et al.  Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Atadja Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[8]  R. Johnstone,et al.  Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. , 2009, Future oncology.

[9]  H. Kovar,et al.  EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation , 2009, Proceedings of the National Academy of Sciences.

[10]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[11]  Stephen L. Lessnick,et al.  EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma , 2008, PloS one.

[12]  A. Unami,et al.  Mechanisms of HDAC inhibitor-induced thrombocytopenia. , 2007, European journal of pharmacology.

[13]  A. Patnaik,et al.  Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule , 2007 .

[14]  P. Gibbs,et al.  Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Bhalla,et al.  A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies , 2006, Clinical Cancer Research.

[16]  Y. Iwamoto,et al.  Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors , 2005, International journal of cancer.

[17]  Y. Iwamoto,et al.  Identification of p21 WAF1/CIP1 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein* , 2003, The Journal of Biological Chemistry.

[18]  Y. Iwamoto,et al.  Identification of p21 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein* , 2003 .